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A
 
BSTRACT
Background:
 
Grass pollen immunotherapy is highly
effective in reducing seasonal hay fever symptoms
and medication requirements. Clinical improvement is
accompanied by a reduction in nasal mucosal eosi-
nophils, although the mechanism is unknown.
 
Methods:
 
Nasal biopsies were taken from 37 adults
before immunotherapy and during the peak pollen
season following 2 years treatment. Biopsies were
processed for immunohistochemistry for CCR3,
adhesion molecules (intercellular adhesion molecule
(ICAM)-1 and vascular cell adhesion molecule
(VCAM)-1) and apoptotic cells (terminal deoxyribonu-
cleotidyl transferase-mediated dUTP–digoxigenin nick
end-labeling; TUNEL), as well as for interleukin (IL)-4
and IL-13 mRNA-positive cells. Results were compared
with eosinophil numbers in the nasal mucosa.
 
Results:
 
Analysis of the clinical data confirmed that
the proportion of patients who showed greater than
60% improvement in symptoms (47 and 15%) and in
rescue medication (79 and 10%) were significant for
the immunotherapy group compared with placebo
group (
 
P
 
 < 0.03 and 
 
P
 
 < 0.02, respectively). Seasonal
increases were observed for VCAM-1 expression
(
 
P
 
 = 0.05) and IL-13 mRNA-expressing cells (
 
P
 
 < 0.05)
in the placebo group, but not in the immunotherapy
group. The differences for VCAM-1 expression achieved
significance between groups (
 
P
 
 = 0.05). There was no
significant difference in either ICAM-1 expression or in
the number of CCR3
 
+
 
 cells, TUNEL
 
+
 
 apoptotic cells
and IL-4 mRNA-expressing cells.
 
Conclusion:
 
Successful grass pollen immunotherapy
was associated with inhibition of seasonal increases in
nasal eosinophils, IL-13 mRNA-expressing cells and
VCAM-1 expression, but no change in CCR3 expres-
sion or in the number of apoptotic cells. The reduction
in eosinophils after immunotherapy may be due to
suppression of eosinophil recruitment to the nasal
mucosa rather than enhanced apoptosis.
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I
 
NTRODUCTION
 
Tissue eosinophilia is a characteristic feature of seasonal
allergic rhinitis.
 
1
 
 A balance between recruitment and
clearance of these cells determines the number of
infiltrating inflammatory cells in the airways.
Adhesion-related events are important in leukocyte
recruitment.
 
2
 
 Leukocyte adhesion to venular endothelium
is an early and obligatory step in leukocyte migration into
tissue and is mediated through binding between mem-
brane receptors on the surface of leukocytes and ligands
on the endothelium. Intercellular adhesion molecule
(ICAM-)1 and vascular cell adhesion molecule (VCAM)-1
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are known endothelial adhesion molecules. Intercellular
adhesion molecule-1 mediates the attachment of all
classes of leukocytes to endothelial cells, whereas
VCAM-1 interacts with very late antigen (VLA)-4, which is
expressed on lymphocytes, eosinophils and basophils,
but not on neutrophils.
 
3,4
 
 Increased expression of
ICAM-1 and VCAM-1 in the nasal mucosa has been
shown to occur following local nasal allergen challenge.
 
5–7
 
Cellular recruitment is modulated not only by cell
adhesion systems, but also by chemotactic signals elicited
through chemokine and chemoattractant receptors. The
C-C chemokine receptor (CCR) 3 is strongly expressed
on eosinophils and is responsible for both migration and
degranulation.
 
8–10
 
 Although the C-C chemokines gener-
ally act on several receptors, eotaxin and eotaxin-2 act
uniquely through CCR3.
 
11
 
 Increased expression of
eotaxin in the nasal mucosa has been shown in patients
with seasonal allergic rhinitis after allergen challenge
 
12
 
and during the pollen season.
 
13
 
The ‘Th2-type’ T lymphocyte responses play an impor-
tant role in human allergic responses. Interleukin (IL)-4
and IL-13 are Th2 T lymphocyte-derived cytokines
involved in the generation of 
 
ε
 
 germline gene transcripts,
the critical first step in inducing B cell class switching
towards IgE synthesis.
 
14,15
 
 In addition, both IL-4 and
IL-13 selectively induce VCAM-1 expression on human
endothelial cells.
 
16,17
 
 Interleukin-13 also upregulates
CD69 expression on blood eosinophils and promotes
eosinophil viability.
 
18
 
 Increased expression of both IL-13
mRNA and protein has been shown in the nasal mucosa
of patients with perennial allergic rhinitis
 
19
 
 and in sea-
sonal hay fever sufferers after allergen challenge.
 
20
 
Eosinophil accumulation in tissues is dependent not
only on the recruitment and migration of eosinophils, but
also on the duration of survival of eosinophils in tissues.
 
21
 
Apoptosis is a form of programmed cell death distinct
from necrosis. Although necrosis may promote inflam-
mation by releasing the cell contents, apoptosis results in
the ‘silent’ clearance of inflammatory cells.
 
22
 
 Thus, apop-
tosis may be vital for the resolution of inflammation. Con-
versely, the inhibition of eosinophilic apoptosis may result
in persistent tissue eosinophilia, as observed in patients
with nasal polyposis.
 
23
 
 In contrast with nasal polyposis,
the presence/absence of apoptosis in the nasal mucosa
with seasonal allergic rhinitis, to our knowledge, has not
been studied.
We recently reported that grass pollen immunotherapy
was effective in patients with severe summer hay fever
unresponsive to usual anti-allergic drugs.
 
24
 
 We observed
that immunotherapy inhibited seasonal increases in
major basic protein (MBP)+ and eosinophil granule-2
(EG2) + eosinophils.
 
25,26
 
 We also observed that reduc-
tions in both EG2+ eosinophils and IL-5 correlated with
the degree of symptomatic improvement after 2 years
immunotherapy.
 
26
 
 In the same study, we have now
explored possible mechanisms for the inhibition of tissue
eosinophilia following immunotherapy. Thus, we studied
the expression of the eosinophil-selective molecule
VCAM-1 and those cytokines responsible for VCAM-1
upregulation, namely IL-4 and IL-13. We also examined
nasal biopsies before and after immunotherapy for eosi-
nophil apoptosis.
 
M
 
ETHODS
 
Patients
 
The clinical features of the 44 patients in the present study
have been reported previously.
 
24
 
 All subjects had a history
of severe summer hay fever that was not controlled by anti-
allergic drugs and a positive skin test reaction (wheal
> 5 mm) to 
 
Phleum pratense
 
 (Timothy grass pollen).
Patients were excluded if they had multiple allergies or had
received immunotherapy within the preceding 5 years.
The mean age of immunotherapy and placebo-
treated patients was 32 and 32 years, respectively. The
gender ratio (M : F) in the two groups was 10 : 12 and
13 : 9, respectively, results of median skin prick tests
(in mm
 
2
 
) were 49.5 and 42.8, respectively, and baseline
hayfever severity (mean weekly visual analog symptom
scores during the baseline pollen season) was 4.4 and
4.5 cm, respectively, on a scale of 0–10 cm. The clinical
data have been reported previously in terms of symptoms
and rescue medication use.
 
24
 
 We now report the clinical
response as a percentage of patients responding by a
given change (worse, improved < 30%, improved
30–59% and improved > 60%) in diary symptom and
medication scores compared with the baseline season
before treatment.
 
Study design
 
The present study was randomized, double blind and
placebo controlled. The active treatment comprised an
aluminum hydroxide adsorbed grass pollen (
 
P. pratense
 
)
extract for subcutaneous injection.
 
24
 
 The placebo
appeared identical and was composed of the allergen
diluent in histamine acid phosphate and induced local
itching and whealing at injection sites. Patients were
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monitored for one summer prior to randomization to
immunotherapy or placebo treatment. Nasal biopsies
were taken at baseline and during the peak pollen
season following 2 years treatment. Paired nasal
biopsies were obtained from 37 of 44 patients who
completed the clinical study (20 immunotherapy and
17 placebo-treated patients). The study was approved by
the Ethics Committee of the Royal Brompton and
Harefield Hospitals NHS Trust and was performed with
the patients’ written informed consent.
 
Nasal biopsy
 
Nasal biopsies (2–5 mm) were taken under local
anesthesia from the under surface of the inferior
turbinate, as described previously.
 
27
 
 For immunohisto-
chemistry, half of each biopsy was mounted in OCT
compound (VWR, Lutterworth, Leics, UK), snap-frozen in
isopentane precooled in liquid nitrogen and stored at
–80
 
°
 
C. For 
 
in situ
 
 detection of apoptotic cells and 
 
in situ
 
hybridization, the other half of each biopsy was placed
in 4% paraformaldehyde for 2 h and then two changes
of 15% sucrose before being mounted in OCT and
snap-frozen as described above.
 
Immunohistochemistry
 
Immunohistochemistry was performed on 6 
 
µ
 
m cryostat
sections fixed in acetone : methanol (60 : 40) by using the
alkaline phosphatase anti-alkaline phosphatase method,
as described previously.
 
28
 
 Briefly, sections were incubated
for 30 min at room temperature with the primary antibody,
followed by 30 min incubation each with rabbit antimouse
antibody and alkaline phosphatase anti-alkaline phos-
phatase complex (both from DAKO, Cambridge, UK). The
reaction was developed with Fast Red, giving positive cells
a red appearance. Monoclonal antibodies used were
BMK13 (a gift from J Barkans/R Moqbel, Allergy and
Clinical Immunology, Imperial College London at National
Heart & Lung Institute, London, UK) for eosinophils against
MBP, EG2 (Pharmacia and Upjohn Diagnostics, Uppsala,
Sweden) for detecting the actively secreted form of eosi-
nophil cationic protein (ECP), CCR3 (7B11; Millennium
Pharmaceuticals, Boston, MA, USA), ICAM-1 (DAKO) and
VCAM-1 (DAKO).
 
Terminal deoxyribonucleotidyl transferase-
mediated dUTP–digoxigenin nick end-labeling
 
Apoptotic cells were detected using the terminal deoxyri-
bonucleotidyl transferase-mediated dUTP–digoxigenin
nick end-labeling (TUNEL) method with TACSXL 
 
in situ
 
apoptosis detection kit (R&D Systems, Minneapolis, MN,
USA).
 
29
 
 The labeling targets are the multitude of new
3
 
′
 
-OH DNA ends generated by DNA fragmentation and
are typically localized in morphologically identifiable
nuclei of apoptotic cells. The assay was performed as
recommended by the manufacturer. Slides were pre-
treated with 3% hydrogen peroxide in methanol. Apop-
totic cells were visualized with diaminobenzidine (DAB)
solution in 0.03% H
 
2
 
O
 
2
 
 and counterstained with hema-
toxylin. As a positive control, the permeabilized sections
were treated with TACS-nuclease and Buffer (R&D Sys-
tems) for 20 min at 37
 
°
 
C and were then stained by the
TUNEL procedure. This resulted in virtually all individual
cell nuclei staining with DAB. In addition, Cell Culture
Control Slides (R&D Systems) were used as an apoptotic
positive control for TUNEL. Negative controls were also
performed with omission of terminal deoxynucleotidyl
transferase.
 
In situ
 
 hybridization
 
Riboprobes (antisense and sense) were prepared from
cDNA for IL-4 and IL-13. The cDNA was inserted into
different pGEM vectors and linearized with appropriate
enzymes before transcription.
 
30
 
 Transcription was per-
formed in the presence of [
 
35
 
S]-labeled uridine triphos-
phate and the appropriate T7 or SP6 RNA polymerizes.
 
In situ
 
 hybridization was performed on 6 
 
µ
 
m cryostat
sections on Polysine™ slides (VWR). Sections were
permeabilized with Triton X-100 in phosphate-buffered
saline (PBS) followed by proteinase K digestion. Sections
were treated with iodoacetamide and 
 
N
 
-ethylmaleimide
and then acetic anhydride–triethanolamine to inhibit
non-specific binding of [
 
35
 
S]. As a negative control,
sections were either hybridized with the sense probe
or treated with ribonuclease A solution before the
prehydration step with antisense probes.
 
Quantitation
 
Biopsy specimens were coded and sections were
assessed in a blinded fashion. Immunoreactivity of
ICAM-1 and VCAM-1 was expressed according to the
modified visual analog scale described by Bentley
 
et al
 
.
 
31
 
 Intensity of staining was scored as follows: 0,
none; 1, weak; 2, moderate; 3, strong; and 4, very
strong. The extent of staining was scored as follows: 0,
none; 0.1, < 1% of section area; 0.2, < 3% of section
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area; 0.5, < 5% of section area; 1, < 10% of section
area; 2, 10–50% of section area; 3, 50–75% of section
area. Cell counts for MBP (BMK13), EG2, CCR3, IL-4
and IL-13 were performed by using an Olympus BH2
microscope (Olympus Optical Company, Tokyo, Japan)
with an eyepiece graticule. Sections were counted to one
grid depth beneath the epithelium and results are
expressed as the number of positive cells per mm
 
2
 
.
 
Statistical analysis
 
Statistical analysis was performed using a commercial
software package (Minitab release 7; Minitab, State
College, PA, USA). Comparisons between measure-
ments obtained before and after treatment in the same
subject were analyzed using the Wilcoxon matched-pairs
signed-ranks test. Comparisons between immuno-
therapy and placebo-treated patients were performed
using the Mann–Whitney 
 
U
 
-test. Correlations were
performed using the Spearman rank correlation method.
 
P
 
 < 0.05 was considered significant.
 
R
 
ESULTS
 
Clinical response to immunotherapy
 
Following 2 years of immunotherapy, the percentages of
patients who showed reductions in symptom scores and
decreases in medication scores during the pollen season
for the immunotherapy were compared with those for the
placebo-treated group (Fig. 1).
 
24
 
 After 2 years treat-
ment, the percentage of patients who showed a greater
than 60% reduction in symptoms during the pollen
season compared with baseline was significantly higher
for the immunotherapy treated patients compared with
placebo patients (47 
 
vs
 
 15%, respectively; 
 
P
 
 < 0.03).
Similarly, the percentage of patients who showed a
greater than 60% reduction in rescue medication
requirements during the pollen season was higher in
 
Fig. 1
 
Percentage reductions in (a,c) symptom and (b,d) medication scores obtained from immunotherapy (a,b) and placebo-
treated (c,d) patients. There was a significant difference between immunotherapy and placebo-treated patients in symptom
(
 
P
 
 < 0.03) and medication (
 
P
 
 < 0.02) scores.
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the immunotherapy group (79 
 
vs
 
 10%, respectively;
 
P
 
 < 0.02).
 
Eosinophils, CCR3, apoptotic cells, IL-4 and 
IL-13
 
In placebo-treated patients, as reported previously,
 
25,26
 
there was a highly significant, greater than five- to
sevenfold increase in the number of MBP+ or EG2+
eosinophils in the nasal mucosa during the pollen
season compared with a one- to 2.5-fold increase in
the  immunotherapy treated group. The peak seasonal
values were significantly different between groups
(Table 1).
There were no significant increases in the number
of CCR3-positive cells in the nasal mucosa (Fig. 2) for
either group and no significant between-group differ-
ences (Table 1).
The TUNEL-positive apoptotic cells (8.3–10.5/mm
 
2
 
)
were detected within the nasal mucosa of both placebo-
and immunotherapy treated subjects (Fig. 2). During
the pollen season, there was no significant difference in
the number of apoptotic cells between the two groups
(Table 1).
The number of cells expressing IL-4 mRNA was low
before treatment and at peak season in both groups.
In contrast, a significant increase was observed in the
number of cells expressing IL-13 mRNA (
 
P
 
 < 0.05)
during the pollen season in placebo-treated subjects,
whereas this was not observed in the immunotherapy
treated group (Figs 2,3; Table 1).
 
Expression of VCAM-1 and ICAM-1
 
Significant increases in both the extent (
 
P
 
 < 0.05) and
the intensity (
 
P
 
 < 0.05) of VCAM-1 staining were
observed in placebo-treated subjects during the pollen
season. These increases were not observed in the
immunotherapy treated group. The differences between
before season and peak season were significantly differ-
ent between groups in the extent of VCAM-1 staining
(
 
P
 
 = 0.05) and a trend for a difference in the intensity of
VCAM-1 staining (
 
P
 
 = 0.08) between the groups was
also observed (Figs 2,3; Table 2). In contrast, no differ-
ences were observed in the expression of ICAM-1 either
at baseline or following 2 years treatment between the
immunotherapy and placebo-treated groups (Table 2).
In patients who had received immunotherapy, there
was no correlation between peak seasonal symptoms
and VCAM-1 (extent) expression (
 
r
 
 = 0.08; 
 
P
 
 = 0.7) or
the number of IL-13 mRNA+ cells (
 
r =
 
 0.3; 
 
P
 
 = 0.16).
Similarly, there was no significant correlation between
MBP+ cells and VCAM-1 (extent) expression (
 
r =
 
 0.3;
 
P
 
 = 0.2) or IL-13 mRNA+ cells (
 
r =
 
 0.4; 
 
P
 
 = 0.08).
 
DISCUSSION
We have shown that grass pollen immunotherapy for
hay fever inhibited seasonal increases in nasal mucosal
eosinophils and that this was accompanied by a
decrease in IL-13 mRNA+ cells and a decrease in both
the extent and intensity of VCAM-1, but not ICAM-1,
staining within the nasal mucosa. In contrast, no sig-
nificant differences were observed in the number of
Table 1 Immunohistochemistry and in situ hybridization of the nasal mucosa
Immunotherapy Placebo Point estimate 
(95%CI)
P †
Before treatment Peak season Before treatment Peak season
Immunohistochemistry
MBP 5.9 (2.7, 11.2) 16.4 (6.8, 75)* 11.3 (2.7, 21) 86 (41,113)** 43.7 (1.2, 80.6) 0.04
EG2 12 (3.2, 21) 14.2 (9.4, 27)* 7.5 (2.8, 28.8) 39.2 (16.4, 76)** 17 (1, 39) 0.04
CCR3 29 (18, 44.9) 34.3 (20, 47.4) 32.5 (20, 43.5) 42 (19.3, 63.8) 7.5 (–7, 22) 0.3
TUNEL ND 8.3 (4.5, 26.3) ND 10.5 (7, 17.2) –1 (–5.3, 8.3) 0.8
In situ hybridization
IL-4 0 (0, 1.1) 0 (0, 1.1) 0 (0, 0.6) 0 (0, 4) 0 (0, 0) 0.9
IL-13 0 (0, 4.6) 0 (0, 6.3) 0 (0, 2) 5.9 (0, 21)* 2.5 (0, 10) 0.1
Data (cells per mm2) are the median with the interquartile range given in parentheses.
†Between-group comparisons (peak season) were performed using the Mann–Whitney U-test.
*P < 0.05,**P < 0.01 (within-group comparisons were performed using the Wilcoxon matched-pairs signed-rank test).
MBP, major basic protein; TUNEL, terminal deoxyribonucleotidyl transferase-mediated dUTP–digoxigenin nick end-labeling; IL, interleukin;
CI, confidence interval.
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apoptotic cells between the groups. There were also no
differences in the number of CCR3-positive cells
between the groups. The present data suggest that the
effect of immunotherapy on nasal mucosal eosinophils
may be mediated, at least in part, by inhibiting IL-13-
induced VCAM-1 expression rather than via enhanced
apoptosis.
The present study was a double-blind and placebo-
controlled trial in which immunological parameters were
correlated with the clinical response to treatment. For
example, there was a correlation between immunotherapy
in duced decreases in eosinophils and symptomatic
improvement following immunotherapy.26 However,
there are some limitations. For example, the trend (not
significant) for an elevated level of VCAM-1 expression
(extent) at baseline in the immunotherapy patients must
have occurred by chance. However, this does not invali-
date the observed differences for VCAM-1 between the
groups because: (i) the analysis was based on the differ-
ences between the baseline and the peak seasonal values
between the groups, an analysis that corrects for the
baseline differences between groups; and (ii) comparable
Fig. 2 Representative examples of immunohistochemistry (IHC) and in situ hybridization (ISH), all samples in peak season.
(a) CCR3+ cells by IHC (alkaline phosphatase anti-alkaline phosphatase technique; positive cells stain red; original magnification
×200). (b) Vascular cell adhesion molecule-1 positive cells by IHC (alkaline phosphatase anti-alkaline phosphatase technique;
positive cells stain red; original magnification ×200). (c) Apoptotic nuclei using the terminal deoxyribonucleotidyl transferase-
mediated dUTP–digoxigenin nick end-labeling (TUNEL) technique (apoptotic nucleus stains brown; original magnification ×1000).
(d) Interleukin-13 mRNA+ cells, identified by ISH (original magnification ×400). Arrows indicate positive cells.
a b c d
Table 2 Intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 staining of the nasal mucosa
Immunotherapy Placebo Point estimate 
(95%CI)
P†
Before treatment Peak season Before treatment Peak season
Intercellular adhesion molecule-1
Intensity 3 (2, 3) 2.5 (2, 3) 3 (2, 3) 2 (2, 3) 0 (–1, 1) 0.9
Extent 1 (1, 2) 2 (1, 2) 1 (1, 2) 2 (1, 2) 0 (–1, 0.5) 0.6
Vascular cell adhesion molecule-1
Intensity 3 (2, 3) 2.5 (2, 3) 2 (2, 2) 3 (2, 3)* –1 (–2, 0) 0.08
Extent 0.5 (0.2, 0.5) 0.2 (0.1, 0.5) 0.1 (0.1, 0.2) 0.2 (0.1, 0.75)* –0.3 (–0.5, 0) 0.05
Data (visual analog scores) are the median with the interquartile range given in parentheses.
†Between-group comparisons (differences between before treatment and peak season) were performed using the Mann–Whitney U-test.
*P < 0.05 (within-group comparisons were performed using the Wilcoxon matched-pairs signed-rank test).
CI, confidence interval.
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results were found for the intensity of VCAM-1 staining
where the baseline values for both groups were compar-
able. Second, there was no correlation between IL-13
and VCAM-1 expression and the clinical response within
the immunotherapy group. However, other factors are
involved in the clinical expression of symptoms, including
the IgE-dependent release of mast cell mediators, sen-
sorineural reflexes and, possibly, the psychological state
of the patients. Finally, no significant correlation was
observed between the number of eosinophils in the nasal
mucosa and the level of IL-13 or VCAM-1 expression.
However, this does not invalidate the association,
because other factors may be involved in determining the
number of tissue eosinophils, such as the degree of
degranulation of eosinophils (with a possible reduction in
the number of eosinophils that can be immunostained)
and the extent to which transepithelial migration of
eosinophils into the nasal lumen may result in loss of
tissue eosinophils.
In patients with allergic rhinitis, the nasal mucosa
contains increased numbers of inflammatory cells, partic-
ularly eosinophils, both after allergen challenge and
during natural seasonal pollen exposure.28 The mecha-
nism of eosinophil accumulation in the nasal mucosa
and how immunotherapy suppresses eosinophilia remain
unclear. We have reported previously that immuno-
therapy inhibits local IL-5 mRNA+ cells and that this
correlated with both the number of eosinophils and
symptomatic improvement during the pollen season.26
Interleukin-5 has a number of properties that effect
recruitment and survival of eosinophils. These include
activation,32–34 adhesion35 and survival.36 It is well
established that IL-5 is one important factor for tissue
eosinophilia.
Fig. 3 (a) Numbers of interleukin (IL)-13 mRNA-positive cells and (b) visual analog scores for the extent of staining of vascular cell
adhesion molecule (VCAM)-1 in the nasal mucosa. Data shown are for baseline (Before) and peak-seasonal (Peak) nasal biopsy
specimens in immunotherapy (IT) and placebo-treated patients. Horizontal lines represent median values. Within-group comparisons
between baseline and peak seasonal scores were performed using the Wilcoxon matched-pairs signed-rank test and comparisons
between immunotherapy and placebo-treated patients were performed using the Mann–Whitney U-test.
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Eosinophil numbers in the airways can be related to a
balance between incoming recruited cells and apoptotic
cells, which undergo phagocytic clearance. The inter-
action between these different but interrelated processes
represents a fine balance that determines the tissue load
of eosinophils.37 Selective recruitment of eosinophils is
influenced by adhesion molecules,16,17 chemokines (e.g.
eotaxin)38,39 and their respective receptors. It has been
demonstrated that eotaxin and CCR3 expression are
increased and related to eosinophil infiltration into the
airways of patients with asthma, suggesting a critical role
for this pathway in airway eosinophilia.40 Large numbers
of CCR3-positive cells in the nasal mucosa were detect-
able at baseline and we were unable to show any increase
in the number of CCR3-positive cells in either group.
One explanation may be that most CCR3-expressing
cells were neither eosinophils nor T lymphocytes, but that
CCR3 was expressed by other cells, such as mast cells.41
Alternatively, CCR3 may be internalized following chem-
okine receptor binding in the tissues.42,43
Leukocyte adhesion to venular endothelium is an early
and obligatory step in leukocyte migration into tissue and
is mediated through binding between membrane adhe-
sion molecules on the surface of leukocytes and ligands
on the vascular endothelium. The endothelial ligands
include ICAM-1 and VCAM-1. Intercellular adhesion
molecule-1 recognizes the β2 leukocyte integrin leuko-
cyte function antigen-1 (LFA-1) and Mac-1, whereas
VCAM-1 binds the β1 integrin VLA-4. Both ligands are
involved in eosinophil recruitment.3,44,45 However, VCAM-1
is more selective for eosinophil recruitment, because its
counter adhesion molecule VLA-4 is expressed by eosi-
nophils and lymphocytes, but not by neutrophils, whereas
LFA-1 and Mac-1 are also expressed by neutrophil leuko-
cytes.16 It has been reported that the expression of ICAM-1
and VCAM-1 is increased in the nasal mucosa in subjects
with perennial allergic rhinitis.46 The expression of ICAM-1
and VCAM-1 in the nasal mucosa increased following
allergen challenge.5–7 Expression of VCAM-1 is known to
be selectively enhanced by both IL-4 and IL-13.16,17 The
effect of IL-13 on VCAM-1 is more potent than that of
IL-4 in human mucosal microvascular endothelial cells.47
Similarly, in allergen-induced late-phase cutaneous res-
ponses, mRNA expression and protein product for IL-13
but not for IL-4 significantly correlated with VCAM-1
immunoreactivity and the number of tissue eosinophils.48
Significantly elevated expression of IL-13 has also been
observed in the nasal mucosa of patients with perennial
allergic rhinitis19 and with seasonal hay fever after
antigen challenge.20 This expression of IL-13 was greater
than that of IL-4. The seasonal increase in the expression
of both VCAM-1 and IL-13 mRNA that we have observed
in placebo-treated patients is consistent with the hypothe-
sis that IL-13 and VCAM-1 cooperatively take part in
eosinophil recruitment.
In nasal polyp tissue, neutralizing concentrations of
anti-IL-5 have been shown to increase eosinophil apop-
tosis and reduce tissue eosinophilia.23 In addition, IL-13
has been shown to enhance eosinophil survival.18 Gluco-
corticoids, such as dexamethasone, can cause a striking
reduction in eosinophil numbers in vivo.49 One way in
which glucocorticoids may exert their effects on eosi-
nophils may be through inducing their apoptosis, either
directly or by inhibiting the production of survival-
enhancing cytokines.21 One recent study in patients with
rhinosinusitis demonstrated that oral administration of
prednisolone induced eosinophilic apoptosis accompa-
nied by a significant decrease in the number of EG2- and
IL-5-positive cells in the sinus mucosa.50 To our knowl-
edge, there are no previously reported measurements of
apoptotic cells in the nasal mucosa in allergic rhinitis, nor
any studies examining the effects of immunotherapy. We
were unable to show any relationship between apoptotic
cells and eosinophil accumulation and no apparent influ-
ence of immunotherapy. One recent study has shown
that lymphocytes derived from immunotherapy treated
patients demonstrated increased allergen-induced apop-
tosis in vitro.51 These increases in apoptotic cells occurred
mainly in IL-4+/CD4+ T lymphocytes.
In conclusion, in patients with hay fever, we have shown
that increased IL-13 and VCAM-1 expression that accom-
panied eosinophil accumulation in the nasal mucosa
during the pollen season was inhibited following successful
immunotherapy, whereas no differences in local numbers
of apoptotic cells were observed. These data suggest that
immunotherapy leads to changes in the local cytokine
milieu that reduce eosinophil infiltration. We suggest that
the mechanism of reduction in eosinophil numbers after
immunotherapy may result from suppression of eosinophil
adhesion/recruitment rather than enhanced apoptosis. This
finding highlights the IL-13–VCAM-1 axis as potential target
for therapeutic intervention in seasonal allergic rhinitis.
ACKNOWLEDGMENTS
This study was supported by Medical Research Council
and National Asthma Campaign UK and ALK Abelló,
Horsholm, Denmark.
GRASS POLLEN IMMUNOTHERAPY 263
REFERENCES
1 Bentley AM, Jacobson MR, Cumberworth V et al.
Immunohistology of the nasal mucosa in seasonal allergic
rhinitis: Increases in activated eosinophils and epithelial
mast cells. J. Allegy Clin. Immunol. 1992; 89: 877–83.
2 Springer TA. Adhesion receptors of the immune system.
Nature 1990; 346: 425–34.
3 Elices MJ, Osborn L, Takada Y et al. VCAM-1 on acti-
vated endothelium interacts with the leukocyte integrin
VLA-4 at a site distinct from the VLA-4/fibronectin binding
site. Cell 1990; 60: 577–84.
4 Bochner BS, Luscinskas FW, Gimbrone Jr MA et al. Adhe-
sion of human basophils, eosinophils, and neutrophils to
interleukin 1-activated human vascular endothelial cells:
Contributions of endothelial cell adhesion molecules.
J. Exp. Med. 1991; 173: 1553–6.
5 Lee BJ, Naclerio RM, Bochner BS, Taylor RM, Lim MC,
Baroody FM. Nasal challenge with allergen upregulates
the local expression of vascular endothelial adhesion
molecules. J. Allergy Clin. Immunol. 1994; 94: 1006–16.
6 Matsui T, Asakura K, Shirasaki H, Kataura A, Himi T.
Relationship between infiltrating cells and adhesion mole-
cules in the nasal mucosa of patients with allergic rhinitis.
Acta Otolaryngol. 2000; 120: 973–80.
7 Braunstahl GJ, Overbeek SE, Kleinjan A, Prins JB,
Hoogsteden HC, Fokkens WJ. Nasal allergen provocation
induces adhesion molecule expression and tissue eosi-
nophilia in upper and lower airways. J. Allergy Clin.
Immunol. 2001; 107: 469–76.
8 Zimmermann N, Conkright JJ, Rothenberg ME. CC chem-
okine receptor-3 undergoes prolonged ligand-induced
internalisation. J. Biol. Chem. 1999; 274: 12 611–18.
9 Fujisawa T, Kato Y, Nagase H et al. Chemokines induce
eosinophil degranulation through CCR-3. J. Allergy Clin.
Immunol. 2000; 106: 507–13.
10 Banderia-Melo C, Herbst A, Weller PF. Eotaxins. Contrib-
uting to the diversity of eosinophil recruitment and activa-
tion. Am. J. Respir. Cell. Mol. Biol. 2001; 24: 653–7.
11 White JR, Imburgia C, Dul E et al. Cloning and functional
characterization of a novel human CC chemokine that
binds to the CCR3 receptor and activates eosinophils.
J. Leukoc. Biol. 1997; 62: 667–75.
12 Minshall EM, Cameron L, Lavigne F et al. Eotaxin mRNA
and protein expression in chronic sinusitis and allergen-
induced nasal responses in seasonal allergic rhinitis. Am.
J. Respir. Cell. Mol. Biol. 1997; 17: 683–90.
13 Pullerits T, Linden A, Praks L, Cardell LO, Lotvall J.
Upregulation of nasal mucosal eotaxin in patients with
allergic rhinitis during grass pollen season: Effect of a
local glucocorticoid. Clin. Exp. Allergy 2000; 30:
1469–75.
14 Punnonen J, Aversa G, Cocks BG et al. Interleukin 13
induces interleukin 4-independent IgG4 and IgE synthesis
and CD23 expression by human B cells. Proc. Natl Acad.
Sci. USA 1993; 90: 3730–4.
15 McKenzie AN, Culpepper JA, de Waal Malefyt R et al.
Interleukin 13, a T-cell-derived cytokine that regulates
human monocyte and B-cell function. Proc. Natl Acad.
Sci. USA 1993; 90: 3735–9.
16 Schleimer RP, Sterbinsky SA, Kaiser J et al. IL-4 induces
adherence of human eosinophils and basophils but not
neutrophils to endothelium. Association with expression of
VCAM-1. J. Immunol. 1992; 148: 1086–92.
17 Bochner BS, Klunk DA, Sterbinsky SA, Coffman RL,
Schleimer RP. IL-13 selectively induces vascular cell adhe-
sion molecule-1 expression in human endothelial cells.
J. Immunol. 1995; 154: 799–803.
18 Luttmann W, Knoechel B, Foerster M, Matthys H,
Virchow Jr JC, Kroegel C. Activation of human eosinophils
by IL-13. Induction of CD69 surface antigen, its relation-
ship to messenger RNA expression, and promotion of
cellular viability. J. Immunol. 1996; 157: 1678–83.
19 Pawankar RU, Okuda M, Hasegawa S et al. Interleukin-
13 expression in the nasal mucosa of perennial allergic
rhinitis. Am. J. Respr. Crit. Care Med. 1995; 152:
2059–67.
20 KleinJan A, Dijkstra MD, Boks SS, Severijnen LA,
Mulder PG, Fokkens WJ. Increase in IL-8, IL-10, IL-13,
and RANTES mRNA levels (in situ hybridization) in the
nasal mucosa after nasal allergen provocation. J. Allergy
Clin. Immunol. 1999; 103: 441–50.
21 Simon HU. Eosinophil apoptosis: Pathophysiologic and
therapeutic implications. Allergy 2000; 55: 910–15.
22 Haslett C. Resolution of acute inflammation and the role
of apoptosis in the tissue fate of granulocytes. Clin. Sci.
1992; 83: 639–48.
23 Simon HU, Yousefi S, Schranz C, Schapowal A, Bachert C,
Blaser K. Direct demonstration of delayed eosinophil
apoptosis as a mechanism causing tissue eosinophilia.
J. Immunol. 1997; 158: 3902–8.
24 Walker SM, Pajno GB, Lima MT, Wilson DR, Durham SR.
Grass pollen immunotherapy for seasonal rhinitis and
asthma: A randomized, controlled trial. J. Allergy Clin.
Immunol. 2001; 107: 87–93.
25 Wilson DR, Irani AM, Walker SM et al. Grass pollen
immunotherapy inhibits seasonal increases in basophils
and eosinophils in the nasal epithelium. Clin. Exp. Allergy
2001; 31: 1705–13.
26 Wilson DR, Nouri-Aria KT, Walker SM et al. Grass pollen
immunotherapy: Symptomatic improvement correlates
with reductions in eosinophils and IL-5 mRNA expression
in the nasal mucosa during the pollen season. J. Allergy
Clin. Immunol. 2001; 107: 971–6.
27 Fokkens WJ, Vroom TM, Gerritsma V, Rijntjes E. A biopsy
method to obtain high quality specimens of nasal mucosa.
Rhinology 1988; 26: 293–5.
28 Varney VA, Jacobson MR, Sudderick RM et al. Immuno-
histology of the nasal mucosa following allergen-induced
rhinitis. Identification of activated T lymphocytes, eosi-
nophils, and neutrophils. Am. Rev. Respir. Dis. 1992;
146: 170–6.
29 Bank N, Kiroycheva M, Singhal PC, Anthony GM,
Southan GJ, Szabo C. Inhibition of nitric oxide synthase
ameliorates cellular injury in sickle cell mouse kidneys.
Kidney Int. 2000; 58: 82–9.
264 H WATANABE ET AL.
30 Nouri-Aria KT, Irani AM, Jacobson MR et al. Basophil
recruitment and IL-4 production during human allergen-
induced late asthma. J. Allergy Clin. Immunol. 2001;
108: 205–11.
31 Bentley AM, Durham SR, Robinson DS et al. Expression of
endothelial and leukocyte adhesion molecules intera-
cellular adhesion molecule-1, E-selectin, and vascular cell
adhesion molecule-1 in the bronchial mucosa in steady-
state and allergen-induced asthma. J. Allergy Clin.
Immunol. 1993; 92: 857–68.
32 Collins PD, Marleau S, Griffiths Johnson DA, Jose PJ,
Williams TJ. Cooperation between interleukin-5 and the
chemokine eotaxin to induce eosinophil accumulation
in vivo. J. Exp. Med. 1995; 182: 1169–74.
33 Rothenberg ME, Petersen J, Stevens RL et al. IL-5-
dependent conversion of normodense human eosinophils
to the hypodense phenotype uses 3T3 fibroblasts for
enhanced viability, accelerated hypodensity, and sustained
antibody-dependent cytotoxicity. J. Immunol. 1989; 143:
2311–16.
34 Lopez AF, Sanderson CJ, Gamble JR, Campbell HD,
Young IG, Vadas MA. Recombinant human interleukin 5
is a selective activator of human eosinophil function.
J. Exp. Med. 1988; 167: 219–24.
35 Walsh GM, Hartnell A, Wardlaw AJ, Kurihara K,
Sanderson CJ, Kay AB. IL-5 enhances the in vitro adhesion
of human eosinophils, but not neutrophils, in a leucocyte
integrin (CD11/18)-dependent manner. Immunology
1990; 71: 258–65.
36 Ishihara K, Satoh I, Ohuchi K. Analysis of the prolongation
of rat eosinophil survival induced by recombinant rat
interleukin-5. Int. Arch. Allergy Immunol. 2000; 122:
36–9.
37 Walsh GM. Eosinophil apoptosis: Mechanisms and
clinical relevance in asthmatic and allergic inflammation.
Br. J. Haematol. 2000; 111: 61–7.
38 Heath H, Qin S, Rao P et al. Chemokine receptor
usage by human eosinophils. The importance of CCR3
demonstrated using an antagonistic monoclonal anti-
body. J. Clin. Invest. 1997; 99: 178–84.
39 Nickel R, Beck LA, Stellato C, Schleimer RP. Chemokines
and allergic disease. J. Allergy Clin. Immunol. 1999; 104:
723–42.
40 Ying S, Meng Q, Zeibecoglou K et al. Eosinophil chemo-
tactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte
chemoattractant protein-3 (MCP-3), and MCP-4), and
C-C chemokine receptor 3 expression in bronchial biop-
sies from atopic and nonatopic (intrinsic) asthmatics.
J. Immunol. 1999; 163: 6321–9.
41 Romagnani P, De Paulis A, Beltrame C et al. Tryptase–
chymase double-positive human mast cells express the
eotaxin receptor CCR3 and are attracted by CCR3-
binding chemokines. Am. J. Pathol. 1999; 155:
1195–204.
42 Nagase H, Kudo K, Izumi S et al. Chemokine receptor
expression profile of eosinophils at inflamed tissue sites:
Decreased CCR3 and increased CXCR4 expression by
lung eosinophils. J. Allergy Clin. Immunol. 2001; 108:
563–9.
43 Liu LY, Jarjour NN, Busse WW, Kelly EA. Chemokine
receptor expression on human eosinophils from peripheral
blood and bronchoalveolar lavage fluid after segmental
antigen challenge. J. Allergy Clin. Immunol. 2003; 112:
556–62.
44 Marlin SD, Springer TA. Purified intercellular adhesion
molecule-1 (ICAM-1) is a ligand for lymphocyte function-
associated antigen 1 (LFA-1). Cell 1987; 51: 813–19.
45 Diamond MS, Staunton DE, de Fougerolles AR et al.
ICAM-1 (CD54): A counter-receptor for Mac-1 (CD11b/
CD18). J. Cell Biol. 1990; 111: 3129–39.
46 Montefort S, Feather IH, Wilson SJ et al. The expression of
leukocyte–endothelial adhesion molecules is increased in
perennial allergic rhinitis. Am. J. Respir. Cell. Mol. Biol.
1992; 7: 393–8.
47 Terada N, Hamano N, Hohki G et al. The potential role
of interleukin-13 in eosinophilic inflammation in nasal
mucosa. Allergy 1998; 53: 690–7.
48 Ying S, Meng Q, Barata LT, Robinson DS, Durham SR,
Kay AB. Associations between IL-13 and IL-4 (mRNA and
protein), vascular cell adhesion molecule-1 expression,
and the infiltration of eosinophils, macrophages, and
T cells in allergen-induced late-phase cutaneous reactions
in atopic subjects. J. Immunol. 1997; 158: 5050–7.
49 Schleimer RP. Effects of glucocorticosteroids on inflam-
matory cells relevant to their therapeutic applications in
asthma. Am. Rev. Respir. Dis. 1990; 141 (Suppl.):
S59–69.
50 Fan GK, Itoh T, Imanaka M, Fujieda S, Takenaka H.
Eosinophilic apoptosis in sinus mucosa: Relationship to
tissue eosinophilia and its resolution in allergic sinusitis.
J. Allergy Clin. Immunol. 2000; 106: 551–8.
51 Guerra F, Carracedo J, Solana-Lara R, Sanchez-Guijo P,
Ramirez R TH2 lymphocytes from atopic patients treated
with immunotherapy undergo rapid apoptosis after culture
with specific allergens. J. Allergy Clin. Immunol. 2001;
107: 647–53.
